Anzeige
Meldung des Tages: Parlaments-Wahl am 08.03.2026: Ist das der Gratis-Katalysator für diese Aktie?

Sanofi Aktie

Aktie
WKN:  920657 ISIN:  FR0000120578 US-Symbol:  SNYNF Branche:  Pharmazeutika Land:  Frankreich
80,69 €
+0,08 €
+0,10%
17:16:09 Uhr
Depot/Watchlist
Marktkapitalisierung *
102,65 Mrd. €
Streubesitz
43,33%
KGV
10,68
Dividende
3,92 EUR
Dividendenrendite
4,76%
Nachhaltigkeits-Score
68 %
Index-Zuordnung
Euro Stoxx 50
Weiter aufwärts? Long handeln - Jetzt mit Hebel 13,51: ME4WWM
Werbung

Ad-hocs

17.12.25 - GlobeNewswire
Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema
Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema Additional orphan designation reinforces Sanofi’s commitment to ...
15.12.25 - GlobeNewswire
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
15.12.25 - GlobeNewswire
Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
Sanofi provides update on tolebrutinib regulatory submission in non-​relapsing secondary progressive multiple sclerosis
11.12.25 - GlobeNewswire
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-​lowering therapy for hemophilia, can offer consistent protection with as ...
04.12.25 - GlobeNewswire
Press Release: Sanofi completes acquisition of Vicebio
Sanofi completes acquisition of Vicebio
25.11.25 - GlobeNewswire
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing ...
14.11.25 - GlobeNewswire
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
07.11.25 - GlobeNewswire
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for ...
28.10.25 - GlobeNewswire
Press release: Sanofi successfully prices USD 3 billion of bond issue
Sanofi successfully prices USD 3 billion of bond issue
24.10.25 - GlobeNewswire
Press release: Q3: continued sales and earnings progress
22.10.25 - GlobeNewswire
Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-...
20.10.25 - GlobeNewswire
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program If approved, Tzield would be ...
20.10.25 - GlobeNewswire
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-​dose
17.10.25 - GlobeNewswire
Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
17.10.25 - GlobeNewswire
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-​vs-host disease
24.09.25 - GlobeNewswire
Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
24.09.25 - GlobeNewswire
Press release: Availability of the Q3 2025 Aide mémoire
Availability of the Q3 2025 Aide mémoire
23.09.25 - GlobeNewswire
Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
Sanofi’s SAR446268 earns US fast track designation for the treatment of non-​congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, ...
22.09.25 - GlobeNewswire
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
Update on the US regulatory review of tolebrutinib in non-​relapsing, secondary progressive multiple sclerosis Paris, September 22, 2025 . The US Food and Drug Administration ...
22.09.25 - GlobeNewswire
Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 ...

Newssuche

Videos

newspaper
10:00 Uhr
So beeinflussen Margins DEIN Trading
Börsentäglich ab 18 Uhr Feierabend-​Trading Live. Teilnahme kostenlos mit diesem Link ... Mehr »